DETROL LA Drug Patent Profile

Which patents cover Detrol La, and what generic alternatives are available?

Detrol La is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in DETROL LA is tolterodine tartrate. There are twenty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tolterodine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Detrol La

A generic version of DETROL LA was approved as tolterodine tartrate by IVAX SUB TEVA PHARMS on February 23^rd, 2015.

Summary for DETROL LA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	16
Patent Applications:	483
Drug Prices:	Drug price information for DETROL LA
What excipients (inactive ingredients) are in DETROL LA?	DETROL LA excipients list
DailyMed Link:	DETROL LA at DailyMed

See drug prices for DETROL LA

See drug sales revenues for DETROL LA

Recent Clinical Trials for DETROL LA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Phase 4
Astellas Scientific & Medical Affairs, Inc.
Astellas Pharma Global Development, Inc.	Phase 4

See all DETROL LA clinical trials

Pharmacology for DETROL LA

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

Paragraph IV (Patent) Challenges for DETROL LA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DETROL LA	Extended-release Capsules	tolterodine tartrate	2 mg and 4 mg	021228	1	2007-07-30

US Patents and Regulatory Information for DETROL LA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-001	Dec 22, 2000	AB	RX	Yes	No
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-002	Dec 22, 2000	AB	RX	Yes	Yes

International Patents for DETROL LA

See the table below for patents covering DETROL LA around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	9915142
Germany	69317898
Eurasian Patent Organization	200000468
Germany	19875024
Norway	951775
Iceland	5537

Supplementary Protection Certificates for DETROL LA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0325571	21/1998	Austria		PRODUCT NAME: TOLTERODIN, SEINE SALZE, RACEMATE UND ENANTIOMERE; NAT. REGISTRATION NO/DATE: 1-22389 UND 1-22390 19980210; FIRST REGISTRATION: SE 13475 UND 13476 19970905
0325571	1998C0031	Belgium		PRODUCT NAME: TOLTERODINI-L-TARTRAS (=TOLTERODINUM); NATL REGISTRATION NO/DATE: 277 IS 301 F 3 19980309; FIRST REGISTRATION: SE 13475 19970905
0325571	C980020	Netherlands		PRODUCT NAME: TOLTERODINE, DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN FYSIOLO GISCH ACCEPTABEL ZUUR, IN HET BIJZONDER TOLTERODINE L-TARTRAAT; NAT. REGISTRATION NO/DATE: RVG 22148, RVG 22149 19980217; FIRST REGISTRATION: SE 13475, 13476 19970905
0325571	SPC/GB98/027	United Kingdom		PRODUCT NAME: TOLTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: SE 13475 19970905; SE 13476 19970905; UK 00032/0222 19980203; UK 00032/0223 19980203

Detrol LA (tolterodine extended-release): Market dynamics and financial trajectory

Last updated: April 25, 2026

What is Detrol LA and how is it positioned in the market?

Detrol LA is tolterodine extended-release (ER), a muscarinic receptor antagonist used for overactive bladder (OAB). It is marketed as a once-daily ER formulation designed to reduce urinary urgency and frequency versus placebo and earlier immediate-release approaches.

Core market role

• Indication: OAB (overactive bladder symptoms).
• Drug class: Antimuscarinic (muscarinic receptor antagonist).
• Delivery form: Extended-release oral tablet (tolterodine ER).

Competitive context The OAB market includes:

• Antimuscarinics: tolterodine ER (Detrol LA), oxybutynin ER, solifenacin, darifenacin, fesoterodine, trospium ER, etc.
• Beta-3 agonists: mirabegron, vibegron.
• Combination strategies: antimuscarinic plus beta-3 agonist (in clinical practice).
• Procedural alternatives: intravesical therapies, neuromodulation.

Tolterodine ER’s commercial strength historically came from:

• Broad payer familiarity and established OAB reimbursement paths.
• Once-daily dosing convenience versus immediate-release formulations.
• Long incumbency that created prescription inertia, even as newer agents entered.

How do market dynamics typically move Detrol LA’s demand?

Detrol LA’s demand trajectory is driven less by therapeutic novelty and more by pricing, payer preference, and formulary placement. Those factors have shifted steadily as:

• Patents aged out and generic competition spread (direct pressure on price and share).
• Beta-3 agents gained share through tolerability profiles and payer placement strategies.
• OAB formularies consolidated around agents with favorable cost-effectiveness and utilization controls.

Determinants that move volume

• Formulary placement: Preferred status is the main swing factor for mature OAB brands.
• Generic substitution: When generic tolterodine ER becomes widely available, brand share typically collapses unless brand pricing and contracting offset.
• Net price erosion: Contracting discounts and pharmacy benefit manager (PBM) steering tend to compress net revenue.
• Prescriber switching: Once a patient transitions to an alternative, re-switching is uncommon in chronic OAB care.

Determinants that move revenue per prescription

• Wholesale acquisition cost vs net price: Brand revenue falls with rebate intensity and PBM contracting.
• Mix shift within OAB: Beta-3 agonists and newer antimuscarinics can shift prescriptions away from tolterodine ER even when antimuscarinics remain used.

What is the financial trajectory implied by patent expiry and generic entry?

Detrol LA is an older branded product, and its financial path is dominated by the classic pattern for mature pharmaceutical franchises:

1. Peak and plateau while branded demand holds.
2. Sharp decline post generic entry as substitution accelerates.
3. Stabilization at a low share level if the brand maintains certain high-friction segments (specific prescriber habits, formularies with incomplete generic penetration, or short-term coverage exceptions).
4. Ongoing net revenue pressure from continued rebate reductions and mix shifts toward competitor mechanisms.

Why the generic pressure is decisive for Detrol LA Tolterodine ER’s active ingredient is no longer proprietary in most major markets, which structurally limits long-term brand revenue. The primary lever becomes the difference between brand net price and generic net price plus how aggressively PBMs steer to cheaper alternatives.

How does competition from antimuscarinics and beta-3 agonists affect Detrol LA economics?

OAB competition has moved from “within-class antimuscarinic choice” to “class contest” between antimuscarinics and beta-3 agonists.

Mechanism shift

• Beta-3 agonists often win payer preference due to a different side-effect profile and patient tolerability patterns that support adherence.
• Antimuscarinics still retain a large segment, but tolterodine ER faces intense within-class competition where formularies can place a subset of agents as preferred.

Economic consequence

• Even if Detrol LA retains prescriptions, the market value per prescription tends to fall as:
  • Net pricing compresses under rebate pressure.
  • Preferred competitor agents take incremental share.
  • Generic antimuscarinics increase substitution pressure across the class.

What do real-world prescribing and payer patterns suggest about Detrol LA market share?

For long-running OAB therapies, observed market behavior typically shows:

• Brand share loss with generic penetration that outpaces any incremental medical use gains.
• Reallocation across OAB classes when a new mechanism enters and receives preferential placement.
• Chronic switching inertia: patients often stay on the initial effective therapy, but once a formulary barrier is introduced, switching can occur quickly for new starts and renewals depending on plan rules.

For Detrol LA, the practical upshot is that its market share is more sensitive to coverage rules than to clinical differentiation.

What can be said about Detrol LA’s financial trajectory at a high level?

Directionally, Detrol LA’s branded financial trajectory is consistent with a mature product undergoing:

• Net revenue compression due to generic competition.
• Share erosion due to both within-class substitution and beta-3 agonist uptake.
• Lower commercialization leverage as PBMs and payers rely on formulary tiering and step edits rather than brand differentiation.

This translates into an economic profile where:

• Gross revenue declines with reduced branded utilization.
• Operating performance becomes dominated by contracting strategy and residual brand preference rather than unit growth.

What are the market risks and upside levers for Detrol LA?

Key risks

• Generic substitution remains structurally dominant once payers and pharmacies standardize on lower-cost ER tolterodine and competing agents.
• Mechanism competition shifts incremental use away from antimuscarinics when beta-3 agents are preferred.
• Formulary churn: preferred-agent lists change with cost and contracting cycles, reducing long-term brand stability.

Potential levers

• Targeted contracting to reduce net-price disadvantage versus preferred generic or competitor agents.
• Niche persistence where specific tolerability, prescriber habits, or patient response profiles sustain a smaller residual brand base.
• Patient continuity: chronic adherence for those already established on tolterodine ER.

How does Detrol LA’s dynamics compare with other mature OAB brands?

The market dynamics described align with how mature OAB products behave once generic entry and beta-3 competition intensify:

• Brands face price and share cliffs post generic launch.
• They then oscillate around low single-digit share levels tied to contracting and formulary exceptions.
• Value migrates toward preferred agents that combine tolerability and cost-effectiveness.

In this environment, Detrol LA’s trajectory behaves like an incumbent antimuscarinic brand rather than a growth platform.

Key Takeaways

• Detrol LA (tolterodine ER) competes in a mature OAB market where formulary placement, generic substitution, and mechanism-level competition govern outcomes.
• Financial trajectory is dominated by generic-driven net revenue erosion and share dilution, with incremental demand increasingly absorbed by preferred agents and beta-3 agonists.
• Upside is limited to residual brand persistence and contracting strategies; downside is structurally tied to ongoing cost-based payer steering.

FAQs

1. Is Detrol LA considered an antimuscarinic or a beta-3 agonist?
   It is an antimuscarinic (tolterodine extended-release).

2. What symptom set does Detrol LA treat?
   It is used for overactive bladder (OAB) symptoms such as urinary urgency and frequency.

3. What drives Detrol LA’s market performance in a mature setting?
   Formulary access, PBM contracting, generic substitution, and switching behavior for new starts.

4. How does beta-3 competition affect older OAB brands like Detrol LA?
   Beta-3 agonists often win payer preference, which redirects incremental OAB demand away from antimuscarinics.

5. Does Detrol LA face structural headwinds from generic entry?
   Yes. Generic availability typically triggers persistent branded revenue and share pressure in chronic-use categories like OAB.

---

References

[1] FDA. Detrol LA (tolterodine tartrate) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/ (accessed via current label availability).